Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.2K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.2K
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lamin B1 safeguards the B cell genome and shapes lymphoma outcome.

HemaSphere·2026
Same author

Corrigendum to "U-RT1 - A new model for Richter transformation" [Neoplasia Volume 23, Issue 1, January 2021, Pages 140-148].

Neoplasia (New York, N.Y.)·2026
Same author

Revisiting clinical response and refractoriness in immune thrombotic thrombocytopenic purpura.

Blood·2026
Same author

NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL.

Leukemia·2025
Same author

[100 years thrombotic thrombocytopenic purpura (TTP) - lessons learned?]

Deutsche medizinische Wochenschrift (1946)·2024
Same author

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.

Blood·2023

Related Experiment Video

Updated: Sep 11, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Microangiopathic Anemia.

Martin Bommer1, Johannes Bloehdorn1

  • 1Alb-Fils Klinikum, Department of Hematology, Oncology, Infectiuous Disease and Palliative Care Medicine, Göppingen, Germany.

Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie
|August 14, 2025
PubMed
Summary

Thrombotic microangiopathy (TMA) is a life-threatening condition requiring urgent diagnosis. ADAMTS13 testing is crucial for classifying TMA and guiding appropriate, timely treatment for better patient outcomes.

Keywords:
Hemolytic uremic syndromeThrombotic microangiopathyThrombotic thrombocytopenic purpura

More Related Videos

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.1K
Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease
08:38

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Published on: August 26, 2017

7.2K

Related Experiment Videos

Last Updated: Sep 11, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.1K
Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease
08:38

Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease

Published on: August 26, 2017

7.2K

Area of Science:

  • Hematology
  • Internal Medicine
  • Pathophysiology

Background:

  • Thrombotic microangiopathy (TMA) encompasses conditions like hemolytic anemia, thrombocytopenia, and organ damage, often resulting from vessel occlusion.
  • TMA is a life-threatening medical emergency necessitating rapid diagnostic workup to determine the underlying cause.
  • Differential diagnosis can be complex, especially in pregnant patients, cancer patients, or when conditions mimic TMA.

Purpose of the Study:

  • To highlight the critical importance of prompt diagnosis and classification of TMA.
  • To emphasize the role of specific diagnostic tests in guiding targeted therapies for TMA.
  • To discuss the challenges in diagnosing TMA and its various subtypes.

Main Methods:

  • ADAMTS13 activity testing is essential for differentiating immune-mediated TMA (iTTP).
  • Assessing ADAMTS13 levels helps distinguish iTTP from other TMA forms like hemolytic uremic syndrome (HUS) and complement-mediated TMA (cmTMA).
  • Review of diagnostic criteria and therapeutic approaches for different TMA classifications.

Main Results:

  • Patients with ADAMTS13 activity below 10 IU/dL are diagnosed with iTTP and require immediate treatment, such as caplacizumab.
  • TMA with ADAMTS13 activity above 10 IU/dL may indicate HUS, cmTMA (formerly atypical HUS), or secondary TMA, often treated with complement inhibitors like eculizumab.
  • Accurate classification based on ADAMTS13 levels and other factors guides the selection of appropriate therapies.

Conclusions:

  • Prompt identification and classification of TMA are vital for initiating life-saving treatments.
  • ADAMTS13 testing serves as the cornerstone for diagnosing iTTP and guiding management strategies.
  • Understanding the diverse etiologies of TMA is crucial for effective patient care and improved prognoses.